Due to the favorable efficacy and safety of TRK inhibitors, the World Sarcoma Network (WSN) recommends that NTRK gene fusion testing should be incorporated into the clinical management of patients with sarcoma.30 This evidence concerns the gene NTRK1 and sarcoma.